TREATMENT WITH ANTI-ALPHA2 INTEGRIN ANTIBODIES
First Claim
1. A method of treating cancer selected from the group consisting of squamous cell cancer, lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer, as well as B-cell lymphoma including low grade/follicular non-Hodgkin'"'"'s lymphoma (NHL);
- small lymphocytic (SL) NHL;
intermediate grade/follicular NHL;
intermediate grade diffuse NHL;
high grade immunoblastic NHL;
high grade lymphoblastic NHL;
high grade small non-cleaved cell NHL;
bulky disease NHL;
mantle cell lymphoma;
AIDS-related lymphoma; and
Waldenstrom'"'"'s Macroglobulinemia;
chronic lymphocytic leukemia (CLL);
acute lymphoblastic leukemia (ALL);
Hairy cell leukemia;
chronic myeloblastic leukemia; and
post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema such as that associated with brain tumors, Meigs'"'"' syndrome, melanoma, mesothelioma, multiple myeloma, fibrosarcoma, osteosarcoma, and epidermoid carcinoma, comprising administering to a subject a therapeutically effective amount of a humanized anti-α
2 integrin antibody comprising a heavy chain variable region comprising the amino acid sequence of (a) HCDR2 (VIWARGFTNYNSALMS, SEQ ID NO;
2), (b) HCDR1 (GFSLTNYGIH, SEQ ID NO;
1), HCDR2 (VIWARGFTNYNSALMS, SEQ ID NO;
2) and HCDR3 (ANDGVYYAMDY, SEQ ID NO;
3), or (c) SEQ ID NO;
40 and/or a light chain variable region comprising the amino acid sequence of (a) an LCDR1 selected from SANSSVNYIH (SEQ ID NO;
4) or SAQSSVNYIH (SEQ ID NO;
112), (b) LCDR2 (DTSKLAS;
SEQ ID NO;
5) and (c) LCDR3 (QQWTTNPLT, SEQ ID NO;
6).
2 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to treatment of cancer. More specifically the invention relates to methods of treating cancer selected from the group consisting of squamous cell cancer, lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer, as well as B-cell lymphoma including low grade/follicular non-Hodgkin'"'"'s lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade/follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom'"'"'s Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema such as that associated with brain tumors, Meigs'"'"' syndrome, melanoma, mesothelioma, multiple myeloma, fibrosarcoma, osteosarcoma and epidermoid carcinoma, by administering antibodies directed to α2β1 integrin.
-
Citations
66 Claims
-
1. A method of treating cancer selected from the group consisting of squamous cell cancer, lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer, as well as B-cell lymphoma including low grade/follicular non-Hodgkin'"'"'s lymphoma (NHL);
- small lymphocytic (SL) NHL;
intermediate grade/follicular NHL;
intermediate grade diffuse NHL;
high grade immunoblastic NHL;
high grade lymphoblastic NHL;
high grade small non-cleaved cell NHL;
bulky disease NHL;
mantle cell lymphoma;
AIDS-related lymphoma; and
Waldenstrom'"'"'s Macroglobulinemia;
chronic lymphocytic leukemia (CLL);
acute lymphoblastic leukemia (ALL);
Hairy cell leukemia;
chronic myeloblastic leukemia; and
post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema such as that associated with brain tumors, Meigs'"'"' syndrome, melanoma, mesothelioma, multiple myeloma, fibrosarcoma, osteosarcoma, and epidermoid carcinoma, comprising administering to a subject a therapeutically effective amount of a humanized anti-α
2 integrin antibody comprising a heavy chain variable region comprising the amino acid sequence of (a) HCDR2 (VIWARGFTNYNSALMS, SEQ ID NO;
2), (b) HCDR1 (GFSLTNYGIH, SEQ ID NO;
1), HCDR2 (VIWARGFTNYNSALMS, SEQ ID NO;
2) and HCDR3 (ANDGVYYAMDY, SEQ ID NO;
3), or (c) SEQ ID NO;
40 and/or a light chain variable region comprising the amino acid sequence of (a) an LCDR1 selected from SANSSVNYIH (SEQ ID NO;
4) or SAQSSVNYIH (SEQ ID NO;
112), (b) LCDR2 (DTSKLAS;
SEQ ID NO;
5) and (c) LCDR3 (QQWTTNPLT, SEQ ID NO;
6). - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)
- small lymphocytic (SL) NHL;
-
36. A method of treating cancer selected from the group consisting of squamous cell cancer, lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer, as well as B-cell lymphoma including low grade/follicular non-Hodgkin'"'"'s lymphoma (NHL);
- small lymphocytic (SL) NHL;
intermediate grade/follicular NHL;
intermediate grade diffuse NHL;
high grade immunoblastic NHL;
high grade lymphoblastic NHL;
high grade small non-cleaved cell NHL;
bulky disease NHL;
mantle cell lymphoma;
AIDS-related lymphoma; and
Waldenstrom'"'"'s Macroglobulinemia;
chronic lymphocytic leukemia (CLL);
acute lymphoblastic leukemia (ALL);
Hairy cell leukemia;
chronic myeloblastic leukemia; and
post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema such as that associated with brain tumors, Meigs'"'"' syndrome, melanoma, mesothelioma, multiple myeloma, fibrosarcoma, osteosarcoma, and epidermoid carcinoma, comprising administering to a subject a composition comprising a therapeutically effective amount of a humanized anti-α
2 integrin antibody comprising a heavy chain variable region comprising the amino acid sequence of (a) HCDR2 (VIWARGFTNYNSALMS, SEQ ID NO;
2), (b) HCDR1 (GFSLTNYGIH, SEQ ID NO;
1), HCDR2 (VIWARGFTNYNSALMS, SEQ ID NO;
2) and HCDR3 (ANDGVYYAMDY, SEQ ID NO;
3), or (c) SEQ ID NO;
40 and/or a light chain variable region comprising the amino acid sequence of (a) an LCDR1 selected from SANSSVNYIH (SEQ ID NO;
4) or SAQSSVNYIH (SEQ ID NO;
112), (b) LCDR2 (DTSKLAS;
SEQ ID NO;
5) and (c) LCDR3 (QQWTTNPLT, SEQ ID NO;
6) and a pharmaceutically acceptable carrier.
- small lymphocytic (SL) NHL;
-
49. A kit for treating cancer selected from the group consisting of squamous cell cancer, lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer, as well as B-cell lymphoma including low grade/follicular non-Hodgkin'"'"'s lymphoma (NHL);
- small lymphocytic (SL) NHL;
intermediate grade/follicular NHL;
intermediate grade diffuse NHL;
high grade immunoblastic NHL;
high grade lymphoblastic NHL;
high grade small non-cleaved cell NHL;
bulky disease NHL;
mantle cell lymphoma;
AIDS-related lymphoma; and
Waldenstrom'"'"'s Macroglobulinemia;
chronic lymphocytic leukemia (CLL);
acute lymphoblastic leukemia (ALL);
Hairy cell leukemia;
chronic myeloblastic leukemia; and
post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema such as that associated with brain tumors, Meigs'"'"' syndrome, melanoma, mesothelioma, multiple myeloma, fibrosarcoma, osteosarcoma, and epidermoid carcinoma, in a human patient comprising a package comprising a humanized anti-α
2 integrin antibody composition comprising a humanized anti-α
2 integrin antibody comprising a heavy chain variable region comprising the amino acid sequence of (a) HCDR2 (VIWARGFTNYNSALMS, SEQ ID NO;
2), (b) HCDR1 (GFSLTNYGIH, SEQ ID NO;
1), HCDR2 (VIWARGFTNYNSALMS, SEQ ID NO;
2) and HCDR3 (ANDGVYYAMDY, SEQ ID NO;
3), or (c) SEQ ID NO;
40 and/or a light chain variable region comprising the amino acid sequence of (a) an LCDR1 selected from SANSSVNYIH (SEQ ID NO;
4) or SAQSSVNYIH (SEQ ID NO;
112), (b) LCDR2 (DTSKLAS;
SEQ ID NO;
5) and (c) LCDR3 (QQWTTNPLT, SEQ ID NO;
6) and instructions for using said humanized anti-α
2 integrin antibody for said treatment. - View Dependent Claims (50, 51, 52, 53, 54, 55, 56, 57)
- small lymphocytic (SL) NHL;
-
58. An article of manufacture comprising a humanized anti-α
- 2 integrin antibody comprising a heavy chain variable region comprising the amino acid sequence of (a) HCDR2 (VIWARGFTNYNSALMS, SEQ ID NO;
2), (b) HCDR1 (GFSLTNYGIH, SEQ ID NO;
1), HCDR2 (VIWARGFTNYNSALMS, SEQ ID NO;
2) and HCDR3 (ANDGVYYAMDY, SEQ ID NO;
3), or (c) SEQ ID NO;
40 and/or a light chain variable region comprising the amino acid sequence of (a) an LCDR1 selected from SANSSVNYIH (SEQ ID NO;
4) or SAQSSVNYIH (SEQ ID NO;
112), (b) LCDR2 (DTSKLAS;
SEQ ID NO;
5) and (c) LCDR3 (QQWTTNPLT, SEQ ID NO;
6) a container and a label indicating the use of said humanized anti-α
2 integrin antibody for treating cancer selected from the group consisting of squamous cell cancer, lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer, as well as B-cell lymphoma including low grade/follicular non-Hodgkin'"'"'s lymphoma (NHL);
small lymphocytic (SL) NHL;
intermediate grade/follicular NHL;
intermediate grade diffuse NHL;
high grade immunoblastic NHL;
high grade lymphoblastic NHL;
high grade small non-cleaved cell NHL;
bulky disease NHL;
mantle cell lymphoma;
AIDS-related lymphoma; and
Waldenstrom'"'"'s Macroglobulinemia;
chronic lymphocytic leukemia (CLL);
acute lymphoblastic leukemia (ALL);
Hairy cell leukemia;
chronic myeloblastic leukemia; and
post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema such as that associated with brain tumors, Meigs'"'"' syndrome, melanoma, mesothelioma, multiple myeloma fibrosarcoma, osteosarcoma and epidermoid carcinoma. - View Dependent Claims (59, 60, 61, 62, 63, 64, 65, 66)
- 2 integrin antibody comprising a heavy chain variable region comprising the amino acid sequence of (a) HCDR2 (VIWARGFTNYNSALMS, SEQ ID NO;
Specification